TCRX TScan Therapeutics, Inc.: institutional ownership and insider trading
64 funds reported holding $37.7M of TScan Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $3.05M, with 5 new positions and 7 funds selling out; over the last 12 months insiders bought $146K and sold $0 on the open market.
Famous investors holding TCRX
- Two Sigma (Two Sigma Investments): $1.91M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $1.30M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $1.14M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $989K, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $537K, 0.0% of the portfolio
Largest institutional holders of TCRX
- Lynx1 Capital Management LP — $7.86M
- BVF INC/IL — $5.45M
- BAKER BROS. ADVISORS LP — $2.73M
- VANGUARD GROUP INC — $2.48M
- VANGUARD CAPITAL MANAGEMENT LLC — $2.12M
- TWO SIGMA INVESTMENTS, LP — $1.91M
- RENAISSANCE TECHNOLOGIES LLC — $1.30M
- ACADIAN ASSET MANAGEMENT LLC — $1.28M
- Deer Management Co. LLC — $1.22M
- MILLENNIUM MANAGEMENT LLC — $1.14M
Recent TCRX insider trades
- Dec 23, 2025: Nichols Weston bought 161,801 shares ($146K)
- May 20, 2025: Nichols Weston bought 2,588,794 shares ($3.11M)
- Dec 13, 2024: Nichols Weston bought 131,800 shares ($386K)
- Nov 15, 2024: Nichols Weston bought 947 shares ($4.11K)
5%+ owners
- Lynx1 Capital Management LP: 13.1% (Schedule 13G/A, filed Aug 14, 2026)
- BVF PARTNERS L P/IL: 10.0% (Schedule 13G/A, filed Aug 14, 2026)
- Readout Capital, LP: 5.4% (Schedule 13G, filed Sep 25, 2026)